Tuesday, April 13, 2021
  • Setup menu at Appearance » Menus and assign menu to Top Bar Navigation
Advertisement
  • AI Development
    • Artificial Intelligence
    • Machine Learning
    • Neural Networks
    • Learn to Code
  • Data
    • Blockchain
    • Big Data
    • Data Science
  • IT Security
    • Internet Privacy
    • Internet Security
  • Marketing
    • Digital Marketing
    • Marketing Technology
  • Technology Companies
  • Crypto News
No Result
View All Result
NikolaNews
  • AI Development
    • Artificial Intelligence
    • Machine Learning
    • Neural Networks
    • Learn to Code
  • Data
    • Blockchain
    • Big Data
    • Data Science
  • IT Security
    • Internet Privacy
    • Internet Security
  • Marketing
    • Digital Marketing
    • Marketing Technology
  • Technology Companies
  • Crypto News
No Result
View All Result
NikolaNews
No Result
View All Result
Home Machine Learning

Keeping It Real: Challenges And Benefits Of Integrating AI And Machine Learning Into Pharma R&D

January 5, 2020
in Machine Learning
Keeping It Real: Challenges And Benefits Of Integrating AI And Machine Learning Into Pharma R&D
585
SHARES
3.3k
VIEWS
Share on FacebookShare on Twitter

Contributed Commentary by Tom O’Leary

January 3, 2020 | Productivity in the pharmaceutical industry is rapidly declining. In fact, the mean projected return on new drug research and development (R&D) investments by a dozen large biopharma firms fell from 10.1% in 2010 to 1.9% in 2018, according to a 2018 report by the Deloitte Centre for Health Solutions. This crisis has created a need to re-think the way clinical trials are conceived, designed and conducted. As such, artificial intelligence (AI)—which is defined as the simulation of human intelligence processes by machines or computers—is poised to transform the industry.

You might also like

AI.Reverie Appoints Former NVIDIA Deep Learning Guru Aayush Prakash as Head of Machine Learning

Machine Learning Approach In Fantasy Sports: Cricket

ANZ Bank: We’ve been using machine learning for 20 years

With the potential to automate processes, increase efficiency and enable more data-driven decisions in pharma R&D, interest in AI-driven solutions is growing steadily among industry leaders. In truth, the market volume for AI-based medical imaging, diagnostics, personal AI assistants, drug discovery, and genomics is projected to reach $10B by 2024. According to an ICON survey of more than 300 executives, managers, and professionals in biopharma and medical device development companies, nearly 80% of respondents said their firms plan to use, or are using, AI or Big Data approaches to improve R&D performance. Moreover, the umbrella category of AI and advanced analytics was seen as the digital technology with the most potential to improve R&D productivity, according to ICON’s 2019 report on digital disruption in biopharma.

While there are various applications of AI, one of the most disruptive is machine learning, which essentially allows the computer to automatically learn and improve its performance based on experience, rather than being continually programmed. Here we describe the various uses of machine learning in pharmaceutical R&D, as well as the challenges to adopting these technologies.

Uses of Machine Learning

Biomarker Development

One area of drug development where AI has substantial implications is in the development of biomarkers. For example, Berg is a biopharmaceutical company that is applying AI-driven modeling to develop diagnostics and biomarkers in the fields of oncology, endocrinology and neurology. In 2017, Sanofi Pasteur announced a partnership with Berg’s Interrogative Biology platform and bAIcis’ artificial intelligence tool. The partnership will allow these two companies to combine their expertise to identify molecular signatures and potential biomarkers for assessing the influenza vaccine immunological response.

Radiology / radiotherapy planning

Radiology and radiotherapy planning is also being impacted by AI, and this industry should anticipate further growth as imaging technology advances. For example, Google’s DeepMind Health is developing machine learning algorithms to detect the differences between healthy and cancerous tissues with the goal to improve the accuracy of radiotherapy while minimising damage to healthy organs at risk.

Clinical trial research

Machine learning also has many potential applications for improving clinical trials. When applied to data sets, such as social media data, genetic information or electronic health records, machine learning can be used to identify clinical trial participants more efficiently. Moreover, it can be used to facilitate remote monitoring and real-time data access to increase safety and patient adherence, and to determine the optimal sample size of a trial, adjust protocols for different trial sites and reduce data errors such as duplicate entries.

Drug discovery

Finally, AI and machine learning have many potential uses in drug discovery. For example, earlier this year, AstraZeneca announced a deal with BenevolentAI, a UK-based company focused on combining computational medicine and advanced AI. The collaboration will combine AstraZeneca’s disease area expertise and large, diverse datasets with BenevolentAI’s AI machine learning capabilities to discover and develop new drugs for chronic kidney disease and idiopathic pulmonary fibrosis.

Barriers to Adoption

Despite the promise of AI and machine learning to transform the industry, putting these technologies into practice comes with a range of challenges. This is mainly due to the lack of relevant expertise and understanding. Some of the challenges that will need to be addressed include:

  • Data governance challenges
  • The need for transparent algorithms to meet drug development regulations
  • Recruiting data science professionals
  • Breaking down data silos
  • Streamlining electronic records

To address these challenges, many pharma and biotechnology companies will continue to shift towards R&D outsourcing as interest in AI-driven technologies continue to rise.

Looking Ahead

AI and machine learning have the potential to address declining ROI in pharmaceutical R&D by improving biomarker development, radiotherapy planning, clinical research, drug discovery and much more. Despite its potential, the complex nature of AI and machine learning, in addition to the need for sophisticated infrastructure, are driving a trend towards outsourcing these capabilities.

Tom O’Leary is CIO at ICON. He can be reached at Thomas.OLeary@iconplc.com.

Credit: Google News

Previous Post

The 6 life-changing tech habits you need this year

Next Post

Machine learning could reveal graphene oxide’s real structure – Physics World

Related Posts

AI.Reverie Appoints Former NVIDIA Deep Learning Guru Aayush Prakash as Head of Machine Learning
Machine Learning

AI.Reverie Appoints Former NVIDIA Deep Learning Guru Aayush Prakash as Head of Machine Learning

April 13, 2021
Machine Learning Approach In Fantasy Sports: Cricket
Machine Learning

Machine Learning Approach In Fantasy Sports: Cricket

April 13, 2021
ANZ Bank: We’ve been using machine learning for 20 years
Machine Learning

ANZ Bank: We’ve been using machine learning for 20 years

April 13, 2021
Data Science And Machine Learning Service Market Growth Due to COVID-19 Spread | ZS, LatentView Analytics, Mango Solutions, Microsoft, International Business Machine – KSU
Machine Learning

Data Science And Machine Learning Service Market Growth Due to COVID-19 Spread | ZS, LatentView Analytics, Mango Solutions, Microsoft, International Business Machine – KSU

April 13, 2021
A.I. For Raspberry Pi Pico: Uctronics TinyML Learning Kit Review
Machine Learning

A.I. For Raspberry Pi Pico: Uctronics TinyML Learning Kit Review

April 13, 2021
Next Post
Machine learning could reveal graphene oxide’s real structure – Physics World

Machine learning could reveal graphene oxide’s real structure – Physics World

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recommended

Plasticity in Deep Learning: Dynamic Adaptations for AI Self-Driving Cars

Plasticity in Deep Learning: Dynamic Adaptations for AI Self-Driving Cars

January 6, 2019
Microsoft, Google Use Artificial Intelligence to Fight Hackers

Microsoft, Google Use Artificial Intelligence to Fight Hackers

January 6, 2019

Categories

  • Artificial Intelligence
  • Big Data
  • Blockchain
  • Crypto News
  • Data Science
  • Digital Marketing
  • Internet Privacy
  • Internet Security
  • Learn to Code
  • Machine Learning
  • Marketing Technology
  • Neural Networks
  • Technology Companies

Don't miss it

Coinbase IPO marks historic first crypto company to enter US stock exchange as Bitcoin rockets
Blockchain

Coinbase IPO marks historic first crypto company to enter US stock exchange as Bitcoin rockets

April 13, 2021
AI.Reverie Appoints Former NVIDIA Deep Learning Guru Aayush Prakash as Head of Machine Learning
Machine Learning

AI.Reverie Appoints Former NVIDIA Deep Learning Guru Aayush Prakash as Head of Machine Learning

April 13, 2021
Music and Artificial Intelligence | by Ryan M. Raiker, MBA | Apr, 2021
Neural Networks

Music and Artificial Intelligence | by Ryan M. Raiker, MBA | Apr, 2021

April 13, 2021
The rise of headless and hybrid CMS: Tuesday’s daily brief
Digital Marketing

The rise of headless and hybrid CMS: Tuesday’s daily brief

April 13, 2021
Brave browser disables Google’s FLoC tracking system
Internet Security

Brave browser disables Google’s FLoC tracking system

April 13, 2021
New NAME:WRECK Vulnerabilities Impact Nearly 100 Million IoT Devices
Internet Privacy

New NAME:WRECK Vulnerabilities Impact Nearly 100 Million IoT Devices

April 13, 2021
NikolaNews

NikolaNews.com is an online News Portal which aims to share news about blockchain, AI, Big Data, and Data Privacy and more!

What’s New Here?

  • Coinbase IPO marks historic first crypto company to enter US stock exchange as Bitcoin rockets April 13, 2021
  • AI.Reverie Appoints Former NVIDIA Deep Learning Guru Aayush Prakash as Head of Machine Learning April 13, 2021
  • Music and Artificial Intelligence | by Ryan M. Raiker, MBA | Apr, 2021 April 13, 2021
  • The rise of headless and hybrid CMS: Tuesday’s daily brief April 13, 2021

Subscribe to get more!

© 2019 NikolaNews.com - Global Tech Updates

No Result
View All Result
  • AI Development
    • Artificial Intelligence
    • Machine Learning
    • Neural Networks
    • Learn to Code
  • Data
    • Blockchain
    • Big Data
    • Data Science
  • IT Security
    • Internet Privacy
    • Internet Security
  • Marketing
    • Digital Marketing
    • Marketing Technology
  • Technology Companies
  • Crypto News

© 2019 NikolaNews.com - Global Tech Updates